Literature DB >> 5286668

Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia.

B C Baguley, E M Falkenhaug.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5286668

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


× No keyword cloud information.
  7 in total

1.  Quantitation of immunoglobulin-bearing lymphocytes and the lymphocyte response to PHA in experimental pyelonephritis.

Authors:  T E Miller; G Simpson; D J Ormrod
Journal:  Clin Exp Immunol       Date:  1975-09       Impact factor: 4.330

Review 2.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 3.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.

Authors:  A L Harris; C Potter; C Bunch; J Boutagy; D J Harvey; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

5.  Antigen presentation as a factor in the protective immune response to renal infection.

Authors:  T E Miller; S Burnham
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

6.  The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3'-amino-2',3'-dideoxycytidine and cytosine arabinoside.

Authors:  W R Mancini
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.

Authors:  L Simpson-Herren; P E Noker; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.